title: Is bevacizumab a culprit of intractable skin ulcers?
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Murayama
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Yuta
authors.initials: Y
authors.lastname: Koike
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Susumu
authors.initials: S
authors.lastname: Ikehara
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Okubo
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Saori
authors.initials: S
authors.lastname: Tomimura
authors.affiliation: Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Utani
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000068258:Bevacizumab / Q000009:adverse effects*; D005260:Female; D006801:Humans; D012883:Skin Ulcer / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D017768:Skin, Artificial; D014945:Wound Healing
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab